SCHEMBL18486372

SCHEMBL18486372

COC(=O)CCc1cccc(-c2ncnc3c2ncn3[C@@H]2O[C@@H]3CO[Si](C(C)(C)C)(C(C)(C)C)O[C@@H]3[C@H]2O[Si](C)(C)C(C)(C)C)c1

nearest known ligand 0.40

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ DNPH1 O43598 12/20 0.40
▸ PDE4A P27815 2/20 0.35
▸ PDE4D Q08499 2/20 0.35
▸ CYP1A2 P05177 1/20 0.35
▸ HTR1A P08908 1/20 0.35
▸ CYP2D6 P10635 1/20 0.35
▸ ADRB3 P13945 1/20 0.35
▸ PTGS2 P35354 1/20 0.35
▸ PDE3A Q14432 1/20 0.35
▸ LMNA P02545 1/20 0.35
▸ SMN1; SMN2 Q16637 1/20 0.35
▸ ADORA3 P0DMS8 2/20 0.35
▸ NPSR1 Q6W5P4 1/20 0.35
▸ RXFP1 Q9HBX9 1/20 0.35
▸ PDE4B Q07343 1/20 0.33
▸ PDE4C Q08493 1/20 0.33
▸ STING1 Q86WV6 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18486288 1.00 DNPH1 (0.40) DNPH1PDE4APDE4DCYP1A2HTR1A
SCHEMBL18486403 0.94 DNPH1 (0.40) DNPH1PDE4APDE4DCYP1A2HTR1A
SCHEMBL18486293 0.90 DNPH1 (0.37) DNPH1PDE4APDE4DCYP1A2HTR1A
SCHEMBL18486390 0.86 DNPH1 (0.49) DNPH1STING1
SCHEMBL17363663 0.86 DNPH1 (0.44) DNPH1PDE4APDE4DPDE4BPDE4C
SCHEMBL16871895 0.86 DNPH1 (0.44) DNPH1PDE4APDE4DPDE4BPDE4C
SCHEMBL17363867 0.84 DNPH1 (0.37) DNPH1RXFP1STING1
SCHEMBL16871738 0.84 DNPH1 (0.37) DNPH1RXFP1STING1
SCHEMBL17363656 0.84 DNPH1 (0.37) DNPH1RXFP1STING1
SCHEMBL17363657 0.84 DNPH1 (0.37) DNPH1RXFP1STING1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3130597-B1 OLIGONUCLEOTIDE HAVING A NON-NATURAL NUCLEOTIDE AT THE 5'-TERMINAL KYOWA KIRIN CO LTD (JP) 2021-11-10 — — EP disclosed
US-10342819-B2 Oligonucleotide having non-natural nucleotide at 5′-terminal thereof KYOWA HAKKO KIRIN CO., LTD. (JP) 2019-07-09 — — US disclosed
US-20170354673-A1 OLIGONUCLEOTIDE HAVING NON-NATURAL NUCLEOTIDE AT 5'-TERMINAL THEREOF KYOWA HAKKO KIRIN CO., LTD. (JP) 2017-12-14 — — US disclosed
EP-3130597-A1 OLIGONUCLEOTIDE HAVING NON-NATURAL NUCLEOTIDE AT 5'-TERMINAL THEREOF Kyowa Hakko Kirin Co., Ltd. (JP) 2017-02-15 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10342819-B2 Oligonucleotide having non-natural nucleotide at 5′-terminal thereof RNGTT, UPF1, NSUN3 DNPH1 2051/4885PDE4A 1079/4885PDE4D 2433/4885
US-20170354673-A1 OLIGONUCLEOTIDE HAVING NON-NATURAL NUCLEOTIDE AT 5'-TERMINAL THEREOF RNGTT, UPF1, NSUN3 DNPH1 2035/4885PDE4A 1065/4885PDE4D 2404/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback